MSLN and neoplasm: Another phase I trial on OC is currently evaluating the safety and efficacy of CAR-T cells based on ten different tumor-specific antibodies in several tumor types; anti-mesothelin and anti-C-met CAR-T cells are among the treatments administered to patients.